Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GVAX vaccine for prostate cancer: Final Phase III data

Final results from the Phase III VITAL-1 trial in 626 patients showed that median survival was

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE